Insulin resistance and exendin-4 treatment for multiple system atrophy.

Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, Gulyani S, Kapogiannis D, Fernagut PO, Meissner WG

Brain : a journal of neurology1 May 2017Cited by 87 (Europe PMC)

PMID28334990PMCIDPMC6248513DOI10.1093/brain/awx044PepBankPUB-28334990

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In transgenic multiple system atrophy mice, exendin‑4 had positive effects on striatal insulin resistance, monomeric α-synuclein load and nigral dopamine neuron survival.
In plain wordsIn mice with multiple system atrophy, exendin‑4 had positive effects on insulin resistance, α-synuclein load and dopamine neuron survival.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedInsulin resistance, α-synuclein load and neuron survival
Study
mousen: not reported in source
Transgenic multiple system atrophy mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
We also observed insulin resistance in the striatum of transgenic multiple system atrophy mice and further demonstrate that the glucagon-like peptide-1 analogue exendin-4, a well-tolerated and Federal Drug Agency-approved antidiabetic drug, has positive effects on insulin resistance and monomeric α-…
Report a problemFND-2833499001

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

02AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Other
In exendin‑4-treated multiple system atrophy mice, neural-derived exosomal phosphorylated IRS-1 levels negatively correlated with nigral dopamine neuron survival.
In plain wordsIn exendin‑4-treated mice, higher neural exosome phosphorylated IRS-1 levels linked to lower dopamine neuron survival.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseExosomal IRS-1 and neuron survival correlation
Study
mousen: not reported in source
Transgenic multiple system atrophy mice
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Additionally, plasma levels of exosomal neural-derived IRS-1 phosphorylated at serine residue 307 (corresponding to serine residue 312 in humans) negatively correlated with survival of nigral dopamine neurons in multiple system atrophy mice treated with exendin-4.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2833499002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04431713

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

University College, Londonn = 5016 Sept 2020 to 22 Mar 2024

Multiple System Atrophy

Trial page ClinicalTrials.govUpdated 27 Jun 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.